Baseline tumor gene expression signatures correlate with chemoimmunotherapy treatment responsiveness in canine B cell lymphoma
Fig 1
Survival outcomes are improved in canine DLBCL patients receiving chemoimmunotherapy who progress after 90 days.
(A) Kaplan-Meier analysis for progression free survival (PFS) and (B) overall survival time (OST) in dogs who progressed before and after 90 days. Both PFS and OST were statistically significant between the groups (p<0.0001.) Tick marks indicate censored patients.